English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, March 3, 2025
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
エーザイ、指定医薬部外品ドリンク「チョコラBBナイトウェル」新発売
Friday, February 28, 2025
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
エーザイ、線維芽細胞増殖因子受容体(FGFR)選択的チロシンキナーゼ阻害剤タスルグラチニブについて中国・香港・マカオ・台湾での開発・販売に関するライセンス契約をSciCloneと締結
Thursday, February 20, 2025
エーザイ、優れた人的資本経営・情報開示に取り組む企業として「人的資本リーダーズ 2024」「人的資本経営品質 ゴールド」に2年連続で選出
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Friday, February 14, 2025
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Monday, February 3, 2025
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
国立長寿医療研究センターとエーザイ、認知機能低下リスクの低減と栄養に関するガイダンス、および 宅配食/ミールキット開発の手引きを作成し、食品関連企業へ提供開始
Tuesday, January 28, 2025
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575